Clinical Trial Update: Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pegcetacoplan for C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulopathy
• Dense Deposit Disease
• Immune Complex Membranoproliferative Glomerulonephritis
• Membranoproliferative Glomerulonephritis

Drugs mentioned

• Pegcetacoplan (Pegcetacoplan)

Snippet

Sponsor: Apellis Pharmaceuticals, Inc. | Conditions: C3G, IC-MPGN | Phase 3 | Status: COMPLETED | Results posted: 2025-08-06